Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms.

Michal M, Berry RS, Rubin BP, Kilpatrick SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P, Hadravsky L, Michalova K, Szep Z, Michal M.

Am J Surg Pathol. 2018 Oct;42(10):1325-1333. doi: 10.1097/PAS.0000000000001109.

PMID:
29957732
2.

Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).

Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A.

Virchows Arch. 2018 May;472(5):815-824. doi: 10.1007/s00428-018-2316-2. Epub 2018 Feb 14.

PMID:
29445891
3.

Molecular cytogenetic characterization of two established ESFT cell lines.

Ishiguro M, Yuki M, Fukushige T, Mizoguchi M, Kaneko Y, Morishige T, Iwasaki H.

Hum Cell. 2017 Jan;30(1):41-48. doi: 10.1007/s13577-016-0145-7. Epub 2016 Sep 9.

PMID:
27613543
4.

Culturally competent care: using the ESFT model in nursing.

Beard KV, Gwanmesia E, Miranda-Diaz G.

Am J Nurs. 2015 Jun;115(6):58-62. doi: 10.1097/01.NAJ.0000466326.99804.c4. No abstract available.

PMID:
26018010
5.

Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience.

Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM.

Am J Clin Oncol. 2017 Apr;40(2):189-193. doi: 10.1097/COC.0000000000000128.

6.

Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.

Roundhill E, Burchill S.

Br J Cancer. 2013 Jul 9;109(1):195-206. doi: 10.1038/bjc.2013.168. Epub 2013 Jun 25.

7.

Heterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxia.

Magwere T, Burchill SA.

PLoS One. 2011;6(12):e28558. doi: 10.1371/journal.pone.0028558. Epub 2011 Dec 8.

8.

PNET/ESFT of the cranial vault: a case report.

Mellai M, Caldera V, Comino A, Fortunato M, Bernucci C, Schiffer D.

Clin Neuropathol. 2010 Nov-Dec;29(6):372-7.

PMID:
21073841
9.

The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility.

Proctor A, Brownhill SC, Burchill SA.

Biochim Biophys Acta. 2009 Apr;1792(4):260-74. doi: 10.1016/j.bbadis.2009.02.011. Epub 2009 Mar 2. Review.

10.

Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.

Brownhill SC, Taylor C, Burchill SA.

Br J Cancer. 2007 Jun 18;96(12):1914-23. Epub 2007 May 29.

11.

Therapy for metastatic ESFT: is it time to ask new questions?

Snyder KM, Mackall CL.

Pediatr Blood Cancer. 2007 Aug;49(2):115-6. No abstract available.

PMID:
17474114
12.

Protection of Ewing's sarcoma family tumor (ESFT) cell line SK-N-MC from betulinic acid induced apoptosis by alpha-DL-tocopherol.

Raghuvar Gopal DV, Narkar AA, Badrinath Y, Mishra KP, Joshi DS.

Toxicol Lett. 2004 Nov 2;153(2):201-12.

PMID:
15451550

Supplemental Content

Loading ...
Support Center